Lurasidone hydrochloride

TargetMol
Product Code: TAR-T1735
Supplier: TargetMol
CodeSizePrice
TAR-T1735-5mg5mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1735-1mL1 mL * 10 mM (in DMSO)£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1735-10mg10mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1735-25mg25mg£129.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1735-50mg50mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1735-100mg100mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1735-200mg200mg£261.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1735-500mg500mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Lurasidone hydrochloride is a thiazole derivative and atypical antipsychotic agent that functions as a dopamine D2 receptor antagonist; serotonin 5-HT2 receptor antagonist, serotonin 5-HT7 receptor antagonist, an antagonist of the adrenergic α2A and α2C receptors, as well as a partial serotonin 5-HT1A receptor agonist. It is used in the treatment of schizophrenia and bipolar disorder.
CAS:
367514-88-3
Formula:
C28H37ClN4O2S
Molecular Weight:
529.14
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.9948
SMILES:
Cl.O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12
Target:
Dopamine Receptor; 5-HT Receptor; Norepinephrine

References

1. Ishibashi T, et al. J Pharmacol Exp Ther, 2010, 334(1), 171-181. 2. Ishiyama T, et al. Eur J Pharmacol, 2007, 572(2-3), 160-170. 3. Enomoto T, et al. Behav Brain Res, 2008, 186(2), 197-207. 4. Fumagalli F, et al. Int J Neuropsychopharmacol, 2012, 15(2), 235-246. 5. Danek P J, W?jcikowski J, Daniel W A. The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions[J]. Pharmacological reports: PR. 2020, 72(6): 1685-1694. 6. Marta Kot, Anna Haduch, Mariusz Papp, W?adys?awa A. Daniel. The effect of chronic treatment with lurasidone on rat liver cytochrome P450 expression and activity in the chronic mild stress (CMS) model of depression [J]. Drug Metabolism and Disposition. 2017, 45(12): 1336-1344.